ORTHO CYCLEN-28
LOE ApproachingNDAORAL-28TABLET
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ortho Cyclen-28 is an oral combined hormonal contraceptive containing norgestimate and ethinyl estradiol, approved in 1989. It is a 28-day cyclic regimen designed to prevent pregnancy through ovulation suppression. The product is indicated for contraception in women of reproductive age.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating shrinking team and transition-focused roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Ortho Cyclen-28 offers limited career growth opportunities given its LOE-approaching status and zero linked job openings. Professionals assigned to this product should expect focus on defensive market strategy, price optimization, and transition planning rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on ORTHO CYCLEN-28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.